Literature DB >> 19017866

Cough and sputum production are associated with frequent exacerbations and hospitalizations in COPD subjects.

Pierre-Régis Burgel1, Pascale Nesme-Meyer2, Pascal Chanez3, Denis Caillaud4, Philippe Carré5, Thierry Perez6, Nicolas Roche7.   

Abstract

BACKGROUND: Epidemiologic studies indicate that chronic cough and sputum production are associated with increased mortality and disease progression in COPD subjects. Our objective was to identify features associated with chronic cough and sputum production in COPD subjects.
METHODS: Cross-sectional analysis of data were obtained in a multicenter (17 university hospitals in France) cohort of COPD patients. The cohort comprised 433 COPD subjects (65 +/- 11 years; FEV(1), 50 +/- 20% predicted). Subjects with (n = 321) and without (n = 112) chronic cough and sputum production were compared.
RESULTS: No significant difference was observed between groups for age, FEV(1), body mass index, and comorbidities. Subjects with chronic cough and sputum production had increased total mean numbers of exacerbations per patient per year (2.20 +/- 2.20 vs 0.97 +/- 1.19, respectively; p < 0.0001), moderate exacerbations (1.80 +/- 2.07 vs 0.66 +/- 0.85, respectively; p < 0.0001), and severe exacerbations requiring hospitalizations (0.43 +/- 0.95 vs 0.22 +/- 0.56, respectively; p < 0.02). The total number of exacerbations per patient per year was the only variable independently associated with chronic cough and sputum production. Frequent exacerbations (two or more per patient per year) occurred in 55% vs 22% of subjects, respectively, with and without chronic cough and sputum production (p < 0.0001). Chronic cough and sputum production and decreased FEV(1) were independently associated with an increased risk of frequent exacerbations and frequent hospitalizations.
CONCLUSIONS: Chronic cough and sputum production are associated with frequent COPD exacerbations, including severe exacerbations requiring hospitalizations.

Entities:  

Mesh:

Year:  2008        PMID: 19017866     DOI: 10.1378/chest.08-2062

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  107 in total

1.  Comparison of clinico-physiologic and CT imaging risk factors for COPD exacerbation.

Authors:  Jung-Wan Yoo; Yoonki Hong; Joon Beom Seo; Eun Jin Chae; Seung Won Ra; Ji-Hyun Lee; Eun Kyung Kim; Seunghee Baek; Tae-Hyung Kim; Woo Jin Kim; Jin Hwa Lee; Sang-Min Lee; Sangyeub Lee; Seong Yong Lim; Tae Rim Shin; Ho Il Yoon; Seung Soo Sheen; Jae Seung Lee; Jin Won Huh; Yeon-Mok Oh; Sang-Do Lee
Journal:  J Korean Med Sci       Date:  2011-11-29       Impact factor: 2.153

2.  Elastase/LPS-exposed mice exhibit impaired innate immune responses to bacterial challenge: role of scavenger receptor A.

Authors:  Shyamala Ganesan; Andrea N Faris; Adam T Comstock; Joanne Sonstein; Jeffrey L Curtis; Uma S Sajjan
Journal:  Am J Pathol       Date:  2011-11-08       Impact factor: 4.307

3.  Phenotypic and genetic heterogeneity among subjects with mild airflow obstruction in COPDGene.

Authors:  Jin Hwa Lee; Michael H Cho; Merry-Lynn N McDonald; Craig P Hersh; Peter J Castaldi; James D Crapo; Emily S Wan; Jennifer G Dy; Yale Chang; Elizabeth A Regan; Megan Hardin; Dawn L DeMeo; Edwin K Silverman
Journal:  Respir Med       Date:  2014-08-11       Impact factor: 3.415

4.  Chronic productive cough is associated with death in smokers with early COPD.

Authors:  Nirupama Putcha; M Bradley Drummond; John E Connett; Paul D Scanlon; Donald P Tashkin; Nadia N Hansel; Robert A Wise
Journal:  COPD       Date:  2013-10-15       Impact factor: 2.409

5.  Chronic Bronchitis: Where Are We Now?

Authors:  Yaniv Dotan; Jennifer Y So; Victor Kim
Journal:  Chronic Obstr Pulm Dis       Date:  2019-04-09

6.  Respiratory impairment and COPD hospitalisation in older persons: a competing risk analysis.

Authors:  Carlos A Vaz Fragoso; John Concato; Gail McAvay; Peter H Van Ness; Thomas M Gill
Journal:  Eur Respir J       Date:  2012-01-20       Impact factor: 16.671

Review 7.  Prevention of Exacerbations in Chronic Obstructive Pulmonary Disease: Knowns and Unknowns.

Authors:  Alvar Agustí; Peter M Calverley; Marc Decramer; Robert A Stockley; Jadwiga A Wedzicha
Journal:  Chronic Obstr Pulm Dis       Date:  2014-09-25

Review 8.  Roflumilast: in chronic obstructive pulmonary disease.

Authors:  Mark Sanford
Journal:  Drugs       Date:  2010-08-20       Impact factor: 9.546

9.  Objective Measurement of Cough Frequency During COPD Exacerbation Convalescence.

Authors:  Michael G Crooks; Yvette Hayman; Andrew Innes; James Williamson; Caroline E Wright; Alyn H Morice
Journal:  Lung       Date:  2015-08-18       Impact factor: 2.584

Review 10.  Chronic bronchitis and chronic obstructive pulmonary disease.

Authors:  Victor Kim; Gerard J Criner
Journal:  Am J Respir Crit Care Med       Date:  2012-11-29       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.